Pipeline Approvals And Global Rollout Will Boost Biosimilar Markets

Key Takeaways

• Accelerating global biosimilar adoption and strategic partnerships expand Alvotech's market reach, boosting future revenue stability and margin potential.
  
• Vertical integration and acquisitions improve operational efficiency and resilience, supporting sustainable earnings growth amid industry-wide cost pressures.
  
• Reliance on unpredictable milestone payments, intense price competition, high fixed costs, heavy partner concentration, and regulatory risks threaten revenue stability, margin health, and long-term profitability.

Catalysts

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

• Alvotech's expanding global rollout and market share gains for its leading biosimilars, especially Humira and STELARA, signal continued growth as payers worldwide accelerate the shift to biosimilars-directly supporting future revenue and cash flow growth.
  
• Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.
  
• Strengthened strategic partnerships (e.g., Advanz Pharma, Teva, Dr. Reddy's) and expanding distribution footprint enable Alvotech to rapidly access new regions and patient pools as governments seek more cost-effective treatment options, likely enhancing future revenue predictability and operating margins.
  
• Investments in vertical integration and acquisitions (Xbrane R&D, Ivers-Lee) improve operational control and cost efficiencies, expected to enhance gross margin resilience and support sustainable earnings growth amid industry-wide margin pressures.
  
• Sustained global trends of aging populations and rising chronic diseases are structurally increasing demand for biologic therapies, expanding the biosimilar addressable market and underpinning long-term revenue visibility and upside for Alvotech.

Alvotech Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Alvotech's revenue will grow by 36.7% annually over the next 3 years.
• Analysts assume that profit margins will increase from 11.3% today to 24.5% in 3 years time.
• Analysts expect earnings to reach $351.8 million (and earnings per share of $1.04) by about August 2028, up from $63.4 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 20.3x on those 2028 earnings, down from 41.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.6x.
• Analysts expect the number of shares outstanding to grow by 2.23% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.94%, as per the Simply Wall St company report.

Alvotech Future Earnings Per Share Growth

Risks

• Alvotech's guidance and revenue recognition are highly dependent on milestone payments tied to regulatory approvals, which are described as "lumpy" and unpredictable-delays in product approvals or shifts in regulatory timelines (such as FDA inspections or BsUFA date movements) could cause significant shortfalls in revenue, impacting both top-line and earnings volatility in the long term.
  
• The biosimilar industry, especially in products like Humira and STELARA, faces intensifying price competition, with management highlighting "very competitive" pricing and unsustainably low offers from rivals-this pressure could lead to deteriorating net margins and erode profitability over the long term, especially as payer cost-containment becomes more aggressive globally.
  
• Heavily increased R&D investment and recent acquisitions (e.g., Xbrane R&D and Ivers-Lee) add to Alvotech's fixed cost base at a time when cash flow, while improved, is still overshadowed by a high debt load ($1,139 million in debt versus $151 million in cash); if future launches or approvals are delayed or underperform, this could threaten liquidity, force dilutive equity issuance, or increase leverage, directly impacting shareholder value.
  
• Alvotech's dependency on a small number of commercialization partners like Teva, Quallent and STADA for market access in key geographies introduces concentration risk-any unfavorable renegotiation, contract termination, or underperformance by these partners could lead to sudden revenue and market share declines, increasing volatility and reducing earnings visibility.
  
• Regulatory scrutiny-particularly increased FDA and global inspections, or shifting standards for biosimilar approvals-remains a material risk; even "ordinary course" delays or raised quality hurdles could slow time-to-market for pipeline assets, limiting revenue growth and risking further lumpiness or outright misses on financial targets.

Valuation

• The analysts have a consensus price target of $17.5 for Alvotech based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.4 billion, earnings will come to $351.8 million, and it would be trading on a PE ratio of 20.3x, assuming you use a discount rate of 6.9%.
  
• Given the current share price of $8.48, the analyst price target of $17.5 is 51.6% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.